Rafferty Asset Management’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $273K | Buy |
88,454
+5,590
| +7% | +$17.3K | ﹤0.01% | 999 |
|
|
2025
Q1 | $289K | Sell |
82,864
-63,939
| -44% | -$223K | ﹤0.01% | 971 |
|
|
2024
Q4 | $480K | Buy |
146,803
+31,782
| +28% | +$104K | ﹤0.01% | 920 |
|
|
2024
Q3 | $443K | Buy |
+115,021
| New | +$443K | ﹤0.01% | 966 |
|
|
2023
Q2 | – | Sell |
-31,693
| Closed | -$96K | – | 1091 |
|
|
2023
Q1 | $96K | Sell |
31,693
-62,812
| -66% | -$190K | ﹤0.01% | 1126 |
|
|
2022
Q4 | $220K | Buy |
94,505
+40,176
| +74% | +$93.6K | ﹤0.01% | 1066 |
|
|
2022
Q3 | $104K | Sell |
54,329
-13,407
| -20% | -$25.7K | ﹤0.01% | 1124 |
|
|
2022
Q2 | $184K | Buy |
67,736
+7,335
| +12% | +$19.9K | ﹤0.01% | 1046 |
|
|
2022
Q1 | $180K | Buy |
60,401
+35,879
| +146% | +$107K | ﹤0.01% | 1156 |
|
|
2021
Q4 | $95K | Buy |
+24,522
| New | +$95K | ﹤0.01% | 1259 |
|